Efficacy and Safety of C2L-OCT-01 PR in Acromegalic Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

February 29, 2008

Study Completion Date

February 29, 2008

Conditions
Acromegaly
Interventions
DRUG

C2L-OCT-01 PR, 30 mg

Administered by deep IM injection (gluteus) on days 1 and 42

DRUG

Octreotide acetate prolonged release, 30 mg

Administered by deep IM (gluteus) on Days 1, 28 and 56

Trial Locations (6)

Unknown

Republican Centre for Medical Rehabilitation and Water-therapy, Minsk

Semmelweis Egyetem Általános Orvostudományi, Budapest

"Institute of Endocrinology C. I. Parhon Bucharest", Bucharest

Institute of Endocrinology, University Clinical Center, Belgrade

Fakultná Nemocnica s Poliklinkou Bratislava, Bratislava

V.P. Komisarenko Institute of Endocrinology and Metabolism, AMS Ukraine, Kiev

Sponsors
All Listed Sponsors
lead

Ambrilia Biopharma, Inc.

INDUSTRY

NCT00616551 - Efficacy and Safety of C2L-OCT-01 PR in Acromegalic Patients | Biotech Hunter | Biotech Hunter